
    
      Two hundred twenty-five patients with AIDS and CMV retinitis are eligible for enrollment in
      Groups A, B, and C of the study, provided that each subject has received and tolerated a
      therapeutic course of intravenous (IV) ganciclovir of at least 4 weeks duration resulting in
      stable retinitis. An additional 100 subjects who have received and tolerated a course of IV
      or oral ganciclovir under any clinical trial of oral ganciclovir sponsored by Syntex Research
      and have stable retinitis may enter into Group D of this study and receive oral ganciclovir.
    
  